Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies.
Carreño JM, McDonald JU, Hurst T, Rigsby P, Atkinson E, Charles L, Nachbagauer R, Behzadi MA, Strohmeier S, Coughlan L, Aydillo T, Brandenburg B, García-Sastre A, Kaszas K, Levine MZ, Manenti A, McDermott AB, Montomoli E, Muchene L, Narpala SR, Perera RAPM, Salisch NC, Valkenburg SA, Zhou F, Engelhardt OG, Krammer F. Carreño JM, et al. Among authors: coughlan l. Vaccines (Basel). 2020 Nov 9;8(4):666. doi: 10.3390/vaccines8040666. Vaccines (Basel). 2020. PMID: 33182279 Free PMC article.
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice.
Bliss CM, Parsons AJ, Nachbagauer R, Hamilton JR, Cappuccini F, Ulaszewska M, Webber JP, Clayton A, Hill AVS, Coughlan L. Bliss CM, et al. Among authors: coughlan l. Mol Ther Methods Clin Dev. 2019 Dec 24;16:108-125. doi: 10.1016/j.omtm.2019.12.003. eCollection 2020 Mar 13. Mol Ther Methods Clin Dev. 2019. PMID: 31934599 Free PMC article.
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.
Freyn AW, Ramos da Silva J, Rosado VC, Bliss CM, Pine M, Mui BL, Tam YK, Madden TD, de Souza Ferreira LC, Weissman D, Krammer F, Coughlan L, Palese P, Pardi N, Nachbagauer R. Freyn AW, et al. Among authors: coughlan l. Mol Ther. 2020 Jul 8;28(7):1569-1584. doi: 10.1016/j.ymthe.2020.04.018. Epub 2020 Apr 19. Mol Ther. 2020. PMID: 32359470 Free PMC article.
Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection.
Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini M. Rathnasinghe R, et al. Among authors: coughlan l. bioRxiv [Preprint]. 2020 Jul 6:2020.07.06.190066. doi: 10.1101/2020.07.06.190066. bioRxiv. 2020. PMID: 32676603 Free PMC article. Updated. Preprint.
Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.
Rathnasinghe R, Strohmeier S, Amanat F, Gillespie VL, Krammer F, García-Sastre A, Coughlan L, Schotsaert M, Uccellini MB. Rathnasinghe R, et al. Among authors: coughlan l. Emerg Microbes Infect. 2020 Dec;9(1):2433-2445. doi: 10.1080/22221751.2020.1838955. Emerg Microbes Infect. 2020. PMID: 33073694 Free PMC article.
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses.
Guthmiller JJ, Lan LY, Fernández-Quintero ML, Han J, Utset HA, Bitar DJ, Hamel NJ, Stovicek O, Li L, Tepora M, Henry C, Neu KE, Dugan HL, Borowska MT, Chen YQ, Liu STH, Stamper CT, Zheng NY, Huang M, Palm AE, García-Sastre A, Nachbagauer R, Palese P, Coughlan L, Krammer F, Ward AB, Liedl KR, Wilson PC. Guthmiller JJ, et al. Among authors: coughlan l. Immunity. 2020 Dec 15;53(6):1230-1244.e5. doi: 10.1016/j.immuni.2020.10.005. Epub 2020 Oct 22. Immunity. 2020. PMID: 33096040 Free PMC article.
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
Jangra S, De Vrieze J, Choi A, Rathnasinghe R, Laghlali G, Uvyn A, Van Herck S, Nuhn L, Deswarte K, Zhong Z, Sanders N, Lienenklaus S, David S, Strohmeier S, Amanat F, Krammer F, Hammad H, Lambrecht BN, Coughlan L, García-Sastre A, De Geest BG, Schotsaert M. Jangra S, et al. Among authors: coughlan l. bioRxiv [Preprint]. 2020 Oct 23:2020.10.23.344085. doi: 10.1101/2020.10.23.344085. bioRxiv. 2020. PMID: 33106810 Free PMC article. Updated. Preprint.
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
Nachbagauer R, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Stadlbauer D, Wilson PC, Aydillo T, Behzadi MA, Bhavsar D, Bliss C, Capuano C, Carreño JM, Chromikova V, Claeys C, Coughlan L, Freyn AW, Gast C, Javier A, Jiang K, Mariottini C, McMahon M, McNeal M, Solórzano A, Strohmeier S, Sun W, Van der Wielen M, Innis BL, García-Sastre A, Palese P, Krammer F. Nachbagauer R, et al. Among authors: coughlan l. Nat Med. 2021 Jan;27(1):106-114. doi: 10.1038/s41591-020-1118-7. Epub 2020 Dec 7. Nat Med. 2021. PMID: 33288923 Clinical Trial.
Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans.
Dugan HL, Guthmiller JJ, Arevalo P, Huang M, Chen YQ, Neu KE, Henry C, Zheng NY, Lan LY, Tepora ME, Stovicek O, Bitar D, Palm AE, Stamper CT, Changrob S, Utset HA, Coughlan L, Krammer F, Cobey S, Wilson PC. Dugan HL, et al. Among authors: coughlan l. Sci Transl Med. 2020 Dec 9;12(573):eabd3601. doi: 10.1126/scitranslmed.abd3601. Sci Transl Med. 2020. PMID: 33298562 Free PMC article.
76 results